277 related articles for article (PubMed ID: 29544454)
1. Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial.
Burock S; Daum S; Keilholz U; Neumann K; Walther W; Stein U
BMC Cancer; 2018 Mar; 18(1):297. PubMed ID: 29544454
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial treatment with statins and niclosamide prevents CRC dissemination by unhinging the MACC1-β-catenin-S100A4 axis of metastasis.
Kortüm B; Radhakrishnan H; Zincke F; Sachse C; Burock S; Keilholz U; Dahlmann M; Walther W; Dittmar G; Kobelt D; Stein U
Oncogene; 2022 Sep; 41(39):4446-4458. PubMed ID: 36008464
[TBL] [Abstract][Full Text] [Related]
3. Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer.
Sack U; Walther W; Scudiero D; Selby M; Kobelt D; Lemm M; Fichtner I; Schlag PM; Shoemaker RH; Stein U
J Natl Cancer Inst; 2011 Jul; 103(13):1018-36. PubMed ID: 21685359
[TBL] [Abstract][Full Text] [Related]
4. S100A4 in Cancer Metastasis: Wnt Signaling-Driven Interventions for Metastasis Restriction.
Dahlmann M; Kobelt D; Walther W; Mudduluru G; Stein U
Cancers (Basel); 2016 Jun; 8(6):. PubMed ID: 27331819
[TBL] [Abstract][Full Text] [Related]
5. The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical and noncanonical Wnt signaling pathway.
Monin MB; Krause P; Stelling R; Bocuk D; Niebert S; Klemm F; Pukrop T; Koenig S
J Surg Res; 2016 Jun; 203(1):193-205. PubMed ID: 27338550
[TBL] [Abstract][Full Text] [Related]
6. S100A4 drives non-small cell lung cancer invasion, associates with poor prognosis, and is effectively targeted by the FDA-approved anti-helminthic agent niclosamide.
Stewart RL; Carpenter BL; West DS; Knifley T; Liu L; Wang C; Weiss HL; Gal TS; Durbin EB; Arnold SM; O'Connor KL; Chen M
Oncotarget; 2016 Jun; 7(23):34630-42. PubMed ID: 27127879
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic silencing of miR-520c leads to induced S100A4 expression and its mediated colorectal cancer progression.
Mudduluru G; Ilm K; Fuchs S; Stein U
Oncotarget; 2017 Mar; 8(13):21081-21094. PubMed ID: 28423501
[TBL] [Abstract][Full Text] [Related]
8. miR-296 inhibits the metastasis and epithelial-mesenchymal transition of colorectal cancer by targeting S100A4.
He Z; Yu L; Luo S; Li M; Li J; Li Q; Sun Y; Wang C
BMC Cancer; 2017 Feb; 17(1):140. PubMed ID: 28209128
[TBL] [Abstract][Full Text] [Related]
9. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial.
Higurashi T; Hosono K; Takahashi H; Komiya Y; Umezawa S; Sakai E; Uchiyama T; Taniguchi L; Hata Y; Uchiyama S; Hattori A; Nagase H; Kessoku T; Arimoto J; Matsuhashi N; Inayama Y; Yamanaka S; Taguri M; Nakajima A
Lancet Oncol; 2016 Apr; 17(4):475-483. PubMed ID: 26947328
[TBL] [Abstract][Full Text] [Related]
10. New insights into niclosamide action: autophagy activation in colorectal cancer.
Newton PT
Biochem J; 2019 Mar; 476(5):779-781. PubMed ID: 30842311
[TBL] [Abstract][Full Text] [Related]
11. Niclosamide: an established antihelminthic drug as a potential therapy against S100A4-mediated metastatic colon tumors.
Helfman DM
J Natl Cancer Inst; 2011 Jul; 103(13):991-2. PubMed ID: 21685360
[No Abstract] [Full Text] [Related]
12. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at the Time of Primary Curative Surgery in Patients with Colorectal Cancer at High Risk for Metachronous Peritoneal Metastases.
Baratti D; Kusamura S; Iusco D; Gimondi S; Pietrantonio F; Milione M; Guaglio M; Bonomi S; Grassi A; Virzì S; Leo E; Deraco M
Ann Surg Oncol; 2017 Jan; 24(1):167-175. PubMed ID: 27519353
[TBL] [Abstract][Full Text] [Related]
13. Repurposing of ingenol mebutate for treating human colorectal cancer by targeting S100 calcium-binding protein A4 (S100A4).
Hsieh YY; Cheng YW; Wei PL; Yang PM
Toxicol Appl Pharmacol; 2022 Aug; 449():116134. PubMed ID: 35724704
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.
Arend RC; Londoño-Joshi AI; Samant RS; Li Y; Conner M; Hidalgo B; Alvarez RD; Landen CN; Straughn JM; Buchsbaum DJ
Gynecol Oncol; 2014 Jul; 134(1):112-20. PubMed ID: 24736023
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II study of S-1 dosing schedule for resected colorectal cancer.
Matsuda C; Uemura M; Nakata K; Shingai T; Nishimura J; Hata T; Ikenaga M; Takemasa I; Mizushima T; Kato T; Ikeda M; Ohue M; Murata K; Hasegawa J; Satoh T; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
BMC Cancer; 2015 Jun; 15():452. PubMed ID: 26036466
[TBL] [Abstract][Full Text] [Related]
16. S100A4 Is a Strong Negative Prognostic Marker and Potential Therapeutic Target in Adenocarcinoma of the Stomach and Esophagus.
Treese C; Hartl K; Pötzsch M; Dahlmann M; von Winterfeld M; Berg E; Hummel M; Timm L; Rau B; Walther W; Daum S; Kobelt D; Stein U
Cells; 2022 Mar; 11(6):. PubMed ID: 35326507
[TBL] [Abstract][Full Text] [Related]
17. Increased expressions of SATB1 and S100A4 are associated with poor prognosis in human colorectal carcinoma.
Niu Y; Wang L; Cheng C; Du C; Lu X; Wang G; Liu J
APMIS; 2015 Feb; 123(2):93-101. PubMed ID: 25257341
[TBL] [Abstract][Full Text] [Related]
18. Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG).
Huiskens J; van Gulik TM; van Lienden KP; Engelbrecht MR; Meijer GA; van Grieken NC; Schriek J; Keijser A; Mol L; Molenaar IQ; Verhoef C; de Jong KP; Dejong KH; Kazemier G; Ruers TM; de Wilt JH; van Tinteren H; Punt CJ
BMC Cancer; 2015 May; 15():365. PubMed ID: 25943574
[TBL] [Abstract][Full Text] [Related]
19. Salinomycin inhibits metastatic colorectal cancer growth and interferes with Wnt/β-catenin signaling in CD133
Klose J; Eissele J; Volz C; Schmitt S; Ritter A; Ying S; Schmidt T; Heger U; Schneider M; Ulrich A
BMC Cancer; 2016 Nov; 16(1):896. PubMed ID: 27855654
[TBL] [Abstract][Full Text] [Related]
20. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
Sartore-Bianchi A; Trusolino L; Martino C; Bencardino K; Lonardi S; Bergamo F; Zagonel V; Leone F; Depetris I; Martinelli E; Troiani T; Ciardiello F; Racca P; Bertotti A; Siravegna G; Torri V; Amatu A; Ghezzi S; Marrapese G; Palmeri L; Valtorta E; Cassingena A; Lauricella C; Vanzulli A; Regge D; Veronese S; Comoglio PM; Bardelli A; Marsoni S; Siena S
Lancet Oncol; 2016 Jun; 17(6):738-746. PubMed ID: 27108243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
